Novel Adenovirus Plus Chemotherapy for Platinum-Resistant Ovarian Cancer
Posted: Wednesday, November 27, 2019
The results of the phase I OCTAVE study, presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract 1031P), support the further study of enadenotucirev (EnAd), a tumor-selective chimeric Ad11/Ad3 group B adenovirus, in conjunction with paclitaxel for the treatment of patients with platinum-resistant epithelial ovarian cancer. “Favorable disease control is noted in this recurrent platinum-resistant population, which is worthy of further investigation,” reported Iain A. McNeish, PhD, of the Imperial College London, London, UK, and colleagues.
This nonrandomized multicenter clinical trial recruited 20 patients with platinum-resistant epithelial ovarian cancer. Patients were intravenously administered with two cycles, three doses per cycle, of 1x1012 viral particles of EnAd in combination with 80 mg/m2 of paclitaxel.
With a median overall survival of 17 months, an overall response rate of 35%, and a median progression-free survival of 3.7 months, the study authors reported “encouraging signals of efficacy.” Pharmacodynamic marker analysis of baseline and treatment biopsies of five out of six patients showed a positive immune response via increased CD8 T-cell infiltration.
Adverse events included fever/flu-like symptoms (n = 8), neutropenia (n = 7), and abdominal pain (n = 4). Serious adverse events occurred in three individuals: staphylococcal skin infection, abdominal pain, and general physical health deterioration, respectively.
Disclosure: For full disclosures of study authors, visit esmo.org.
